REDWOOD CITY, CA / ACCESSWIRE / August 15, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced its financial results for its fiscal 2023 first quarter ended June 30, 2022.
Dr. Waqaas Al-Siddiq, Founder & CEO of Biotricity, commented, "We are pleased with our year-over-year revenue growth and ability to maintain gross margins at 60% as we begin to roll out our new Biotres and Bioheart products lines through our established network. Both new product offerings will complement the existing platform we have built through Bioflux to make the Biotricity ecosystem an all-in-one go-to solution for cardiologists. Additionally, because Biotres is a higher volume wireless wearable cardiac monitoring device as compared to Bioflux, we expect to expand our distribution to include channels such as Hospital Networks or Integrated Delivery Networks."
Q1-FY23 Financial Highlights:
- Revenue totaled $2.1 million.
- Gross profit totaled $1.2 million.
- Gross profit margins were 60% and consistent with the full year FY22.
- Net loss totaled $5 million or $0.098 per share; adjusted loss per share, a non- GAAP measure, was $0.085 per share after removing certain non-recurring expenses.
Operating Highlights for the FY22 to Date:
- After receiving FDA 510(k) clearance in January 2022, in April 2022, Biotricity officially launched wireless wearable holter patch device, Biotres, a revolutionary holter technology.
- Unveiled Biokit, a personal medical device kit for integration into the Biotricity ecosystem.
- Launched Bioheart, one of the first heart rhythm recorders and personal heart lifestyle solutions.
- Expanded our network to cover 29 states with over 2,000 physicians using our product.
Full details of the Company's financial results will be filed with the SEC on Form 10-Q by visiting www.sec.gov.
Financial Results Conference Call
Management will host a conference call on Monday, August 15, 2022 at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 first quarter and provide a business update. Additional details are available under the Investor Relations section of the Company's website:
Event: | Biotricity Fiscal First Quarter 2023 Financial Results Conference Call |
Date: | Monday, August 15, 2022 |
Time: | 4:30 p.m. Eastern Time |
Live Call: | 1-888-220-8451 (U.S. Toll-Free) or 1-646-828-8193 (International) |
Webcast: | |
For interested individuals unable to join the conference call, a dial-in replay of the call will be available until August 29, 2022 and can be accessed by dialing +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International) and entering replay pin number: 2688378.
About Biotricity:
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit .
Important Cautions Regarding Forward Looking Statements:
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. There cannot be any assurance that the Company will ever become profitable. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Use of Non-GAAP Information
In addition to the unaudited results presented in accordance with generally accepted accounting principles, or GAAP in this press release, Biotricity presents adjusted net loss, which is a non-GAAP financial measure. Adjusted net loss is determined by deducting one-time derivative fair value and accretion expenses from net loss attributable to common shareholders. Our definition of adjusted net loss may not be comparable to the definitions of similarly titled measures used by other companies. We believe that this non-GAAP financial measure, viewed in addition to and not in lieu of its reported GAAP results, provides useful information to investors by providing a more focused measure of operating results. This metric is used as part of the Company's internal reporting to evaluate its operations and the performance of senior management.
The following reconciliation calculates the adjusted loss per share:
| 3 months ended June 30, 2022 | |
| | $ | |
Net loss attributable to common stockholders | | | (5,024,389 | ) |
Add: | | | | |
Provision for income taxes | | | - | |
Interest expense | | | 388,388 | |
Depreciation expense | | | 1,488 | |
| | | (4,634,512 | ) |
Add (Less) | | | | |
Other (income) expense related to convertible note conversion | | | 50,908 | |
Fair value change on derivative liabilities | | | 198,224 | |
Adjusted EBITDA | | | (4,385,381 | ) |
Weighted average number of common shares outstanding | | | 51,440,944 | |
Adjusted Loss per Share, Basic and Diluted | | | (0.085 | ) |
Contacts:
Investor Relations:
KCSA Strategic Communications
Valter Pinto or Jack Perkins
(212) 896-1254
investors@biotricity.com
Media Relations:
Erica Fiorini, Russo Partners
(212) 845-4253
Erica.Fiorini@russopartnersllc.com
BIOTRICITY INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
AS AT JUNE 30, 2022 (unaudited) AND MARCH 31, 2022 (audited)
(Expressed in US Dollars)
| As at June 30, 2022 | | | As at March 31, 2022 | |
| $ | | | $ | |
CURRENT ASSETS | | | | | | |
Cash | | | 7,207,974 | | | | 12,066,929 | |
Accounts receivable, net | | | 1,826,920 | | | | 2,006,678 | |
Inventory | | | 1,431,054 | | | | 842,924 | |
Deposits and other receivables | | | 380,592 | | | | 406,280 | |
Total current assets | | | 10,846,540 | | | | 15,322,811 | |
Deposits | | | 85,000 | | | | 85,000 | |
Long-term accounts receivable | | | - | | | | - | |
Property and equipment | | | 25,970 | | | | 27,459 | |
Operating right-of-use lease asset [Note 10] | | | 1,192,169 | | | | 1,242,700 | |
TOTAL ASSETS | | | 12,149,679 | | | | 16,677,970 | |
CURRENT LIABILITIES | | | | | | | | |
Accounts payable and accrued liabilities [Note 4] | | | 2,701,077 | | | | 2,595,747 | |
Convertible promissory notes and short term loans [Note 5] | | | 1,238,000 | | | | 1,540,000 | |
Derivative liabilities [Note 8] | | | 419,332 | | | | 520,747 | |
Operating lease liability [Note 10] | | | 219,033 | | | | 210,320 | |
Total current liabilities | | | 4,577,442 | | | | 4,866,814 | |
Federally guaranteed loans [Note 7] | | | 870,800 | | | | 870,800 | |
Term loan [Note 6] | | | 11,662,742 | | | | 11,612,672 | |
Derivative liabilities [Note 8] | | | 537,318 | | | | 352,402 | |
Operating lease liability [Note 10] | | | 1,061,795 | | | | 1,120,018 | |
TOTAL LIABILITIES | | | 18,710,097 | | | | 18,822,706 | |
STOCKHOLDERS' EQUITY (DEFICIENCY) | | | | | | | | |
Preferred stock, $0.001 par value, 10,000,000 authorized as at June 30, 2022 and March 31, 2022, respectively, 1 share issued and outstanding as at June 30, 2022 and March 31, 2022, respectively [Note 9] | | | 1 | | | | 1 | |
Preferred stock, $0.001 par value, 20,000 authorized as at June 30, 2022 and March 31, 2022, respectively, 6,872 and 7,201 preferred shares issued and outstanding as at June 30, 2022 and as at March 31, 2022, respectively [Note 9] | | | 8 | | | | 7 | |
Preferred stock | | | 1 | | | | 1 | |
Common stock, $0.001 par value, 125,000,000 authorized as at June 30, 2022 and March 31, 2022, respectively. Issued and outstanding common shares: 50,219,034 and 49,810,322 as at June 30, 2022 and March 31, 2022, respectively, and exchangeable shares of 1,466,718 and 1,466,718 outstanding as at June 30, 2022 and March 31, 2022, respectively [Note 9] | | | 51,685 | | | | 51,277 | |
Shares to be issued 95,515 and 123,817 shares of common stock as at June 30, 2022 and March 31, 2022, respectively) [Note 9] | | | 72,299 | | | | 102,299 | |
Additional paid-in-capital | | | 91,912,772 | | | | 91,507,478 | |
Accumulated other comprehensive loss | | | (535,653 | ) | | | (768,656 | ) |
Accumulated deficit | | | (98,061,531 | ) | | | (93,037,142 | ) |
Total stockholders' equity (deficiency) | | | (6,560,418 | ) | | | (2,144,736 | ) |
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY | | | 12,149,679 | | | | 16,677,970 | |
BIOTRICITY INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
FOR THE THREE MONTHS ENDED JUNE 31, 2022 AND 2021 (unaudited)
(Expressed in US Dollars)
| 3 Months Ended June 30, 2022 | | | 3 Months Ended June 30, 2021 | |
| | $ | | | $ | |
REVENUE | | | 2,056,052 | | | | 1,764,110 | |
Cost of Revenue | | | 830,923 | | | | 525,426 | |
GROSS PROFIT | | | 1,225,129 | | | | 1,238,684 | |
EXPENSES | | | | | | | | |
General and administrative expenses [Notes 8, 9 and 10] | | | 4,881,003 | | | | 3,652,203 | |
Research and development expenses | | | 821,176 | | | | 588,997 | |
TOTAL OPERATING EXPENSES | | | 5,702,179 | | | | 4,241,200 | |
Other (income)/expense [Note 8] [Note 9] | | | - | | | | (8,782 | ) |
Loss upon convertible promissory notes conversion | | | 50,908 | | | | 28,215 | |
Accretion and amortization expenses [Note 5] [Note 6] | | | 50,070 | | | | 2,335,167 | |
Change in fair value of derivative liabilities [Note 8] | | | 198,224 | | | | 298,983 | |
NET LOSS BEFORE INCOME TAXES | | | (4,776,252 | ) | | | (5,656,099 | ) |
Income taxes | | | - | | | | - | |
NET LOSS BEFORE DIVIDENDS | | | (4,776,252 | ) | | | (5,656,099 | ) |
Less: Preferred Stock Dividends | | | 248,137 | | | | 241,264 | |
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS | | | (5,024,389 | ) | | | 5,897,363 | |
Translation adjustment | | | 233,003 | | | | 6,560 | |
COMPREHENSIVE LOSS | | | (4,791,386 | ) | | | (5,890,803 | ) |
LOSS PER SHARE, BASIC AND DILUTED | | | (0.098 | ) | | | (0.151 | ) |
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING | | | 51,440,944 | | | | 39,095,637 | |
BIOTRICITY INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED JUNE 30, 2022 AND 2021 (UNAUDITED)
(Expressed in US Dollars)
| Three Months Ended June 30, 2022 | | | Three Months Ended June 30, 2021 | |
| | $ | | | $ | |
CASH FLOWS FROM OPERATING ACTIVITIES | | | | | | |
Net loss | | | (4,776,252 | ) | | | (5,656,099 | ) |
Adjustments to reconcile net loss to net cash used in operations | | | | | | | | |
Stock based compensation | | | 149,190 | | | | 155,851 | |
Issuance of shares for services | | | 7,051 | | | | - | |
Issuance of warrants for services | | | 77,414 | | | | 151,897 | |
Accretion and amortization expenses | | | - | | | | 2,335,167 | |
Change in fair value of derivative liabilities | | | 198,224 | | | | 298,983 | |
Loss on debt | | | 50,908 | | | | 28,213 | |
Property, plant and equipment depreciation | | | 1,488 | | | | - | |
Changes in operating assets and liabilities: | | | | | | | | |
Accounts receivable, net | | | 179,758 | | | | (401,818 | ) |
Inventory | | | (588,130 | ) | | | 92,694 | |
Deposits and other receivables | | | (4,312 | ) | | | (86,221 | ) |
Accounts payable and accrued liabilities | | | 416,047 | | | | 399,937 | |
Net cash used in operating activities | | | (4,288,164 | ) | | | (2,681,396 | ) |
CASH FLOWS FROM INVESTING ACTIVITIES | | | | | | | | |
property, plant and equipment | | | - | | | | - | |
Net cash used in investing activities | | | - | | | | - | |
CASH FLOWS FROM FINANCING ACTIVITIES | | | | | | | | |
Issuance of common shares, net | | | - | | | | - | |
Issuance of preferred shares, net | | | - | | | | - | |
Redemption of preferred shares | | | (328,904 | ) | | | - | |
Exercise of warrants for cash | | | - | | | | 146,250 | |
Federally guaranteed loans | | | - | | | | 499,900 | |
Proceeds from (repayment to) convertible notes, net | | | - | | | | - | |
Proceeds from (repayment to) convertible debentures, net | | | - | | | | 139,780 | |
Issuance of shares from uplisting | | | - | | | | - | |
Proceeds pursuant to term loan, net | | | 50,070 | | | | - | |
Preferred Stock Dividend | | | (516,817 | ) | | | (204,842 | ) |
Net cash provided by financing activities | | | (795,651 | ) | | | 581,088 | |
Effect of foreign currency translation | | | 224,860 | | | | 100,334 | |
Net increase (decrease) in cash during the period | | | (5,083,815 | ) | | | (1,999,974 | ) |
Cash, beginning of period | | | 12,066,929 | | | | 2,201,562 | |
Cash, end of period | | | 7,207,974 | | | | 201,588 | |
SOURCE: Biotricity, Inc.
View source version on accesswire.com:
カリフォルニア州レイドウッドシティ/ACCESSWIRE/2022年8月15日/医療診断と消費者保健技術会社Biotricity Inc.(ナスダックコード:BTCY)(以下、“会社”と略す)は今日、2022年6月30日までの2023年度第1四半期の財務業績を発表した。
Biotricity創業者で最高経営責任者のWaqaas Al-Siddiq博士は、“私たちが構築したネットワークを介して新しいBiotresとBioHeart製品ラインを発売し始めるにつれて、収入の前年比増加と毛金利が60%を維持する能力を喜んでいる。この2つの新製品はBioFluxを通じて設立された既存のプラットフォームを補完し、Biotricity生態系を心臓病の専門家のワンストップ解決策にする。また、BiotresはBioflowよりも容量の大きい無線ウェアラブル心臓監視装置であるため、病院ネットワークや統合配信ネットワークなどのルートを拡大することが予想される”と述べた
第1四半期から23年度までの財務ハイライト:
- 総収入は210万ドルです。
- 毛利益は合計120万ドルです。
- 毛金利は60%で、22年度通年並みだった。
- 純損失は合計500万ドル、あるいは1株0.098ドルである;調整後の1株当たり損失(非公認会計基準測定基準)は、ある非日常的な費用を差し引いて1株当たり0.085ドルである。
これまでの22年度の運営ポイント:
- 2022年1月にFDA 510(K)の承認を得た後、2022年4月、Biotricityは正式に無線ウェアラブルHolterパッチ装置Biotresを発売し、これは革命的なHolter技術である。
- Biotricity生態系に統合された個人医療機器キットであるBiokitを発売しました
- 最初の心臓リズム記録器と個人心臓生活様式の解決策の一つであるBioHeartを発売した。
- 私たちのネットワークを29州に拡張して2,000人以上の医師が私たちの製品を使用しています
会社の財務業績のすべての詳細は10-Q表形式で米国証券取引委員会に提出され、サイトはwww.sec.govである。
財務業績電話会議
経営陣は2022年8月15日(月)午後4時30分に電話会議を主宰する。ETはその2023年度第1四半期の財務業績を検討し、業務の最新状況を提供する。もっと詳しく知りたいのですが、会社のサイト投資家関係欄に登録してください
イベント: | Biotricity会計年度2023年第1四半期財務業績電話会議 |
日付: | 2022年8月15日(月) |
時間: | 午後四時三十分東部時間 |
現場通話: | 1-888-220-8451(米国無料)または1-646-828-8193(国際) |
インターネット中継: | |
電話会議に参加できない興味のある個人については、2022年8月29日までに電話再放送をダイヤルすることができ、+1−844−512−2921(米国無料)または+1−412−317−6671(国際)にダイヤルし、再放送パスワード:2688378を入力することによって聴くことができる。
Biotricity社について:
Biotricityは遠隔モニタリングと慢性看護管理の格差を埋めることでヘルスケア市場を改革している。医師と患者は慢性病の診断と診断後の解決策を含むBiotricity比類のない予防とパーソナルケア基準を信頼している。同社は医療と消費市場のために全面的な遠隔健康モニタリングソリューションを開発している。もっと情報を知るためには訪問してください。
前向きな陳述に関する重要な警告:
本プレスリリースに含まれる歴史的事実を記述しないいかなる陳述も前向きな陳述を構成する可能性がある。前向きな陳述は、我々の将来の計画、戦略、および予期を仮定して説明することに関し、一般に、“可能”、“すべき”、“将”、“将”、“可能”、“予定”、“予想”、“予想”、“推定”、“信じる”、“意図”、“求める”、“プロジェクト”または“目標”またはこれらの語または同様の用語の他の変形を使用することによって識別することができる。前向きな陳述は、(I)BioFluxまたは会社の任意の他の提案された製品またはサービスの設計、開発および商業化に関連する計画、目標、または目標を含む将来の経営の計画、目標、および目標、(Ii)収入(収益/損失を含む)、1株当たりの収益(収益/損失を含む)、資本支出、配当、資本構造、または他の財務プロジェクトの予測、(Iii)会社の将来の財務業績、を含むことができるが、これらに限定されない。(Iv)当社が運営または運営しようとする規制制度および(V)上記(I)、(Ii)、(Iii)または(Iv)点で説明された任意の陳述に基づいているか、または関連する仮定。このような展望的陳述は、実際の結果、業績、イベントまたは状況を予測または保証するためではなく、実現できないかもしれない。それらは会社の現在の予測、計画、目標、信念、予想、推定と仮定に基づいており、多くのリスク、不確定要素、およびその他の影響を受けるからである, その多くは会社がコントロールできない。これらのリスクおよび不確実性のため、いくつかのイベントおよび状況の実際の結果および時間は、前向き陳述に記載されているものとは大きく異なる可能性がある。展望性陳述の不正確さに影響したり、実際の結果が期待や予想結果と大きく異なる要素を招く可能性があるが、これらに限定されない可能性があり、企業は追加融資を得ることができない、製品開発に関連する大量の時間と資源、および関連するキャッシュフローの不足と原因の流動性不足、会社は会社の業務を拡大することができず、政府の医療機器や保健業界に対する重大な規制、製品の多様性の不足、既存あるいは激化した競争、仲裁と訴訟の結果、株式変動と流動性不足、そして会社が会社の業務計画や戦略を実行できなかった。これらの要因および他の要因は、同社が米国証券取引委員会に提出した文書でより詳細な識別および記述を得ている。その会社が永遠に利益を上げることは保証されない。当社は、本プレスリリースの日以降に発生する可能性のあるいかなる事件や状況を反映するために、いかなる前向き陳述も更新する義務はありません。
非公認会計原則情報の使用
Biotricityは、公認会計原則または本プレスリリースのGAAPによって公表された未監査の結果に加えて、非GAAP財務測定基準である調整後の純損失を公表する。調整後の純損失は普通株株主が純損失を占めて一度の派生公正価値と付加価値費用を引いて確定しなければならない。調整後の純損失の定義は,他社が使用している類似見出し尺度の定義と比較できない可能性がある。この非GAAP財務指標はその報告されたGAAP結果の補充であり、それに代わるのではなく、より的確な経営業績指標を提供することによって、投資家に有用な情報を提供したと考えられる。この指標は、その運営と上級経営陣の業績を評価するために、社内報告の一部として使用される。
以下、帳簿計算調整後の1株当たり損失:
| 3ヶ月 一段落した 2022年6月30日 | |
| | $ | |
普通株主は純損失を占めなければならない | | | (5,024,389 | ) |
追加: | | | | |
所得税支給 | | | - | |
利子支出 | | | 388,388 | |
減価償却費用 | | | 1,488 | |
EBITDA | | | (4,634,512 | ) |
プラス(マイナス) | | | | |
変換可能チケット変換に関するその他の(収益)費用 | | | 50,908 | |
派生負債の公正価値変動 | | | 198,224 | |
調整後EBITDA | | | (4,385,381 | ) |
発行済み普通株式加重平均 | | | 51,440,944 | |
調整後の1株当たり基本損失と希釈後の1株当たり損失 | | | (0.085 | ) |
連絡先:
投資家関係:
KCSA戦略伝播
ワルター·平トーやジャック·パーキンス
(212) 896-1254
メールボックス:Investors@Biotrity.com
メディア関係:
エリカ·フィオリニRusso Partners
(212) 845-4253
メールボックス:Erica.Fiorini@russopartnersllc.com
BIOTRICITY Inc.
簡明合併貸借対照表
2022年6月30日まで(監査なし)、2022年3月31日(監査済み)
(ドルで表す)
| 2022年6月30日まで | | | 2022年3月31日まで | |
| $ | | | $ | |
流動資産 | | | | | | |
現金 | | | 7,207,974 | | | | 12,066,929 | |
売掛金純額 | | | 1,826,920 | | | | 2,006,678 | |
在庫品 | | | 1,431,054 | | | | 842,924 | |
保証金とその他の入金 | | | 380,592 | | | | 406,280 | |
流動資産総額 | | | 10,846,540 | | | | 15,322,811 | |
預金.預金 | | | 85,000 | | | | 85,000 | |
長期売掛金 | | | - | | | | - | |
財産と設備 | | | 25,970 | | | | 27,459 | |
経営的使用権リース資産[注10] | | | 1,192,169 | | | | 1,242,700 | |
総資産 | | | 12,149,679 | | | | 16,677,970 | |
流動負債 | | | | | | | | |
売掛金と売掛金[注4] | | | 2,701,077 | | | | 2,595,747 | |
本チケットと短期ローンを転換することができます[注5] | | | 1,238,000 | | | | 1,540,000 | |
派生負債[注8] | | | 419,332 | | | | 520,747 | |
リース負債を経営する[注10] | | | 219,033 | | | | 210,320 | |
流動負債総額 | | | 4,577,442 | | | | 4,866,814 | |
連邦保証融資[注7] | | | 870,800 | | | | 870,800 | |
定期ローン[注6] | | | 11,662,742 | | | | 11,612,672 | |
派生負債[注8] | | | 537,318 | | | | 352,402 | |
リース負債を経営する[注10] | | | 1,061,795 | | | | 1,120,018 | |
総負債 | | | 18,710,097 | | | | 18,822,706 | |
株主権益(不足) | | | | | | | | |
優先株、額面0.001ドル、2022年6月30日及び2022年3月31日にそれぞれ1,000,000株を承認し、それぞれ2022年6月30日及び2022年3月31日に1株を発行及び発行する[注9] | | | 1 | | | | 1 | |
優先株は、額面0.001ドル、2022年6月30日と2022年3月31日までそれぞれ20,000株、発行済み優先株と発行済み優先株はそれぞれ6,872株と7,201株である[注9] | | | 8 | | | | 7 | |
優先株 | | | 1 | | | | 1 | |
普通株は、額面0.001ドルで、2022年6月30日と2022年3月31日までにそれぞれ1.25億株を許可する。発行済みと発行済み普通株:2022年6月30日と2022年3月31日までそれぞれ50,219,034株と49,810,322株であり、2022年6月30日と2022年3月31日までにそれぞれ1,466,718株と1,466,718株の交換可能株式である[注9] | | | 51,685 | | | | 51,277 | |
2022年6月30日および2022年3月31日にそれぞれ95,515株および123,817株普通株を発行)[注9] | | | 72,299 | | | | 102,299 | |
実収資本を追加する | | | 91,912,772 | | | | 91,507,478 | |
その他の総合損失を累計する | | | (535,653 | ) | | | (768,656 | ) |
赤字を累計する | | | (98,061,531 | ) | | | (93,037,142 | ) |
株主権益合計 | | | (6,560,418 | ) | | | (2,144,736 | ) |
総負債と株主の欠員 | | | 12,149,679 | | | | 16,677,970 | |
BIOTRICITY Inc.
経営報告書と全面赤字を簡明に合併する
2022年6月31日と2021年6月31日までの3ヶ月(監査なし)
(ドルで表す)
| 3ヶ月まで 2022年6月30日 | | | 3ヶ月まで 2021年6月30日 | |
| | $ | | | $ | |
収入.収入 | | | 2,056,052 | | | | 1,764,110 | |
収入コスト | | | 830,923 | | | | 525,426 | |
毛利 | | | 1,225,129 | | | | 1,238,684 | |
費用.費用 | | | | | | | | |
一般と行政費用[付記8、9及び10] | | | 4,881,003 | | | | 3,652,203 | |
研究開発費 | | | 821,176 | | | | 588,997 | |
総運営費 | | | 5,702,179 | | | | 4,241,200 | |
その他(収入)/支出[注8][注9] | | | - | | | | (8,782 | ) |
転換本チケットは損失を両替することができます | | | 50,908 | | | | 28,215 | |
累積と償却費用[注5][注6] | | | 50,070 | | | | 2,335,167 | |
派生負債の公正価値変動[注8] | | | 198,224 | | | | 298,983 | |
所得税前純損失 | | | (4,776,252 | ) | | | (5,656,099 | ) |
所得税 | | | - | | | | - | |
配当金を出す前に純損失を出す | | | (4,776,252 | ) | | | (5,656,099 | ) |
減算:優先株式配当金 | | | 248,137 | | | | 241,264 | |
普通株主は純損失を占めなければならない | | | (5,024,389 | ) | | | 5,897,363 | |
翻訳調整 | | | 233,003 | | | | 6,560 | |
総合損失 | | | (4,791,386 | ) | | | (5,890,803 | ) |
1株当たり基本損失と希釈して1株当たり損失 | | | (0.098 | ) | | | (0.151 | ) |
発行済み普通株式加重平均 | | | 51,440,944 | | | | 39,095,637 | |
BIOTRICITY Inc.
簡明合併現金フロー表
2022年6月30日と2021年6月30日までの3ヶ月(監査なし)
(ドルで表す)
| 2022年6月30日までの3ヶ月 | | | 2021年6月30日までの3ヶ月 | |
| | $ | | | $ | |
経営活動のキャッシュフロー | | | | | | |
純損失 | | | (4,776,252 | ) | | | (5,656,099 | ) |
純損失と運営に使用する純現金を調節するように調整する | | | | | | | | |
株に基づく報酬 | | | 149,190 | | | | 155,851 | |
サービスのために株式を発行する | | | 7,051 | | | | - | |
サービスのために株式承認証を発行する | | | 77,414 | | | | 151,897 | |
累積と償却費用 | | | - | | | | 2,335,167 | |
派生負債の公正価値変動 | | | 198,224 | | | | 298,983 | |
債務損失 | | | 50,908 | | | | 28,213 | |
財産·工場·設備の減価償却 | | | 1,488 | | | | - | |
経営性資産と負債変動状況: | | | | | | | | |
売掛金純額 | | | 179,758 | | | | (401,818 | ) |
在庫品 | | | (588,130 | ) | | | 92,694 | |
保証金とその他の入金 | | | (4,312 | ) | | | (86,221 | ) |
売掛金と売掛金 | | | 416,047 | | | | 399,937 | |
経営活動のための現金純額 | | | (4,288,164 | ) | | | (2,681,396 | ) |
投資活動によるキャッシュフロー | | | | | | | | |
財産·工場·設備 | | | - | | | | - | |
投資活動のための現金純額 | | | - | | | | - | |
融資活動によるキャッシュフロー | | | | | | | | |
普通株発行,純額 | | | - | | | | - | |
優先株を発行し,純額 | | | - | | | | - | |
優先株の償還 | | | (328,904 | ) | | | - | |
現金持分証を行使する | | | - | | | | 146,250 | |
連邦保証融資 | | | - | | | | 499,900 | |
転換可能手形収益(償還)純額 | | | - | | | | - | |
転換可能債券収益(償還)、純額 | | | - | | | | 139,780 | |
上場で株を発行する | | | - | | | | - | |
定期融資によって得られた収益,純額 | | | 50,070 | | | | - | |
優先株配当 | | | (516,817 | ) | | | (204,842 | ) |
融資活動が提供する現金純額 | | | (795,651 | ) | | | 581,088 | |
外貨換算の影響 | | | 224,860 | | | | 100,334 | |
期間内現金純増(減額) | | | (5,083,815 | ) | | | (1,999,974 | ) |
期初の現金 | | | 12,066,929 | | | | 2,201,562 | |
期末現金 | | | 7,207,974 | | | | 201,588 | |
資料源:Biotricity,Inc.
Accesswire.comでソースコードバージョンを表示する: